Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private investors, to fund late-stage trials of Corxel's lead drug CX11, an oral GLP-1 receptor agonist showing promising weight loss results. The merger is expected to close in the first half of 2027, with Corxel US becoming a subsidiary of the new public company listed on Nasdaq. This move aims to support Corxel's growth and development of innovative oral therapies for obesity and related conditions.
Corxel US and Amanat Acquisition Corp's merger to form a public obesity-focused biopharmaceutical company is notable context for readers. For those tracking the health sector, here is Pluang's market snapshot as of Oct 26, 2026 15:11 WIB: out of 150 priced Health-sector US stocks, 70 rose and 32 fell. Key movers include RVMD at USD 190.58 (+1.85%), ERAS at USD 14.15 (-1.67%), and TAK at USD 20.56 (+1.58%).
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
Bavarian Nordic A/S has repurchased shares totaling 964,213 at an average price of DKK 222.22, spending approximately DKK 214 million under its share buy-back program initiated on September 1, 2026. The program, set to run until October 30, 2026, aim...
